Title:
ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE
Document Type and Number:
WIPO Patent Application WO/2012/122058
Kind Code:
A3
Abstract:
The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
Inventors:
SHEN WANG (US)
ZHANG AIMIN (US)
MAUNG JACK (US)
ZHENG XIAOLING (US)
ZHANG AIMIN (US)
MAUNG JACK (US)
ZHENG XIAOLING (US)
Application Number:
PCT/US2012/027614
Publication Date:
April 24, 2014
Filing Date:
March 02, 2012
Export Citation:
Assignee:
NEWGEN THERAPEUTICS INC (US)
SHEN WANG (US)
ZHANG AIMIN (US)
MAUNG JACK (US)
ZHENG XIAOLING (US)
SHEN WANG (US)
ZHANG AIMIN (US)
MAUNG JACK (US)
ZHENG XIAOLING (US)
International Classes:
A61K31/4706
Foreign References:
| US20060270668A1 | 2006-11-30 | |||
| US20060089382A1 | 2006-04-27 | |||
| US20040116422A1 | 2004-06-17 | |||
| US6225318B1 | 2001-05-01 | |||
| US6414148B1 | 2002-07-02 |
Other References:
See also references of EP 2680850A4
Attorney, Agent or Firm:
TIAN, Zong-Qiang Bill et al. (755 Page Mill RoadPalo Alto, CA, US)
Download PDF:
Previous Patent: CATALYSTS FOR THE REDUCTION OF CARBON DIOXIDE TO METHANOL
Next Patent: HYDROGEN BOND SURROGATE MACROCYCLES AS MODULATORS OF RAS
Next Patent: HYDROGEN BOND SURROGATE MACROCYCLES AS MODULATORS OF RAS